Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07319793 | Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT | not yet recruiting | N/A | 200 | Peking University People's HospitalOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT01252485 | Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project(AMLSG BiO) | recruiting | — | 50,000 | University of UlmOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03912064 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | active not recruiting | Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05184842 | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | recruiting | Phase 2 | 91 | Montefiore Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05199051 | A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML(AGORA-1) | active not recruiting | Phase 2 | 19 | Centre Antoine LacassagneOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06452732 | Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML | recruiting | — | 283 | Peking University People's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03326310 | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | recruiting | Phase 1 | 18 | University of ChicagoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05657639 | CAV Regimen for R/R AML | recruiting | Phase 2 | 68 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07296445 | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)(LATITUDE) | not yet recruiting | Phase 3 | 120 | SDK Therapeutics, Inc.INDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07304232 | Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML(CM-AML-001) | recruiting | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05105152 | PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML | recruiting | Phase 1 | 18 | Seattle Children's HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera(SLN) | active not recruiting | Phase 1 / Phase 2 | 69 | Silence Therapeutics plcINDUSTRY | 9 | Dec 19, 2025 | clinicaltrials |
| NCT03654768 | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 81 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06541249 | MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial(TREATMORE) | recruiting | Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06552416 | Safety of MT-401-OTS in Patients With Relapsed AML or MDS(RAPID) | recruiting | Phase 1 | 40 | Marker Therapeutics, Inc.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07121140 | Home Blood Transfusions | recruiting | N/A | 30 | Thomas Jefferson UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07153068 | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06680752 | Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS | recruiting | Phase 1 / Phase 2 | 49 | ARCE Therapeutics, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03828773 | PTX3-targeted Antifungal Prophylaxis(PTX3AML) | recruiting | N/A | 410 | Bochud Pierre-YvesOTHER | 3 | Dec 9, 2025 | clinicaltrials |
| NCT04167683 | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant | active not recruiting | — | 144 | Rigshospitalet, DenmarkOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06782971 | Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX(COSMOS-Avatar) | recruiting | — | 25 | Clinical Hub for Interventional Research (CHOIR)OTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06906380 | A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies | not yet recruiting | — | 49 | ARCE Therapeutics, Inc.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05024552 | Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | recruiting | Phase 1 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06649227 | Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19(CARLA-M19) | recruiting | Phase 1 | 5 | University Hospital, LilleOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03300492 | Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS | recruiting | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05194397 | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors(IAMFIT) | recruiting | Phase 2 | 80 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263906 | Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia | recruiting | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 / Phase 3 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Dec 4, 2025 | clinicaltrials |
| NCT07259161 | Modified Conditioning Regimen for CML-BP | not yet recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT02483312 | A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) | active not recruiting | Phase 1 | 9 | University Health Network, TorontoOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256210 | Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06377579 | OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia | recruiting | — | 250 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | recruiting | Phase 3 | 486 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Nov 25, 2025 | clinicaltrials |
| NCT07244367 | Maintenance Venetoclax in AML Fit Patients | recruiting | N/A | 80 | Sohag UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05566054 | Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia | recruiting | Phase 2 | 92 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06421025 | Blood Viscosity in Polycythemia Patients(POLYVISCO) | recruiting | — | 160 | Hospices Civils de LyonOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07232134 | The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia(AML-DS-2025) | recruiting | Phase 3 | 100 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07238712 | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor(APTBCy) | recruiting | Phase 2 | 60 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06532552 | Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 172 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04070443 | Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase(TIPI) | active not recruiting | Phase 2 | 170 | Centre Leon BerardOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07232953 | Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia(FT14) | active not recruiting | Phase 2 | 82 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07233018 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 24 | MEI HENGOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | recruiting | Phase 2 | 240 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02143830 | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy(RAFA) | recruiting | Phase 2 | 70 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04817241 | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | active not recruiting | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05986240 | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | recruiting | Phase 1 | 38 | Montefiore Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06472128 | Novel Digital Application for Patients With Acute Leukemia(NAVIGATE) | recruiting | N/A | 200 | Massachusetts General HospitalOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | recruiting | Phase 1 | 242 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Nov 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 6, 2026source: clinicaltrials